Hanall Biopharma (009420) stock
KOSPI · Pharmaceuticals
- Market cap
- KRW 2.7 trillion
- As of Nov 16, 2026
- P/E
- -119.86x
- Trailing twelve months
- P/B
- 17.23x
- Latest reported equity
- P/S
- 16.41x
- Trailing twelve months
- ROE
- -14.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 2.7 trillion
- As of Nov 16, 2026
- P/E
- -119.86x
- Trailing twelve months
- P/B
- 17.23x
- Latest reported equity
- P/S
- 16.41x
- Trailing twelve months
- ROE
- -14.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-119.86x
Net loss — not comparable
P/B
17.23x
P/S
16.41x
Earnings and dividend metrics▾
Earnings
EPS
-KRW 424
Earnings per share
BPS
KRW 2,949
Book value per share
ROE
-14.4%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at KRW 424 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 2,949 of net assets.
- ROE — shareholder equity shrank by 14.4% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q3 2026Consolidated · Filed Nov 13, 2026 | KRW 39.9 billion | KRW 1.3 billion | KRW 3.1 billion | -2.2% |
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 44.3 billion | KRW 5.6 billion | -KRW 19.2 billion | +8.8% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 40 billion | KRW 800 million | KRW 300 million | +10.7% |
| Q4 2025Consolidated · Filed Mar 18, 2026 | KRW 37.5 billion | -KRW 2 billion | -KRW 6.2 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 40.8 billion | KRW 300 million | KRW 300 million | +10.8% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 40.7 billion | KRW 1.1 billion | KRW 600 million | +28.8% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 18, 2026 | KRW 155.2 billion | -KRW 900 million | -KRW 5.6 billion | — |
| FY2024Consolidated · Filed Mar 18, 2025 | KRW 138.9 billion | KRW 200 million | -KRW 1.8 billion | — |
- Q3 2026 is computed as 9M 2026 minus H1 2026.
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 11.83%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 2.32 billion
- Previous 20-day average 7.44%
- Net short position
- 596,187 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 3,520,224 shares
- As of Nov 13, 2026 · 6.74% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 11.83% | KRW 2.32 billion |
| Nov 12, 2026 | 19.99% | KRW 5.79 billion |
| Nov 11, 2026 | 11.52% | KRW 4.91 billion |
| Nov 10, 2026 | 7.22% | KRW 4.31 billion |
| Nov 9, 2026 | 4.19% | KRW 500 million |
| Nov 6, 2026 | 2.61% | KRW 320 million |
| Nov 5, 2026 | 5.47% | KRW 830 million |
| Nov 4, 2026 | 12.32% | KRW 1.54 billion |
| Nov 3, 2026 | 1.67% | KRW 80 million |
| Nov 2, 2026 | 8.57% | KRW 460 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Preliminary Consolidated Operating Results (Fair Disclosure)Oct 28, 2026 · Preliminary EarningsEnglish
- Report on Specified Securities Held by Executives and Major ShareholdersOct 6, 2026 · Insider Ownership ReportEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)Jul 29, 2026 · Preliminary Earnings
- [Amended] Material Management Information for Investment Decisions(Korean)Jul 22, 2026 · Material Management Information
- Material Management Information for Investment Decisions(Korean)Jul 22, 2026 · Material Management Information
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Jul 2, 2026 · Insider Ownership Report
- Report on Major Holdings of Shares (Short Form)(Korean)Jul 1, 2026 · Major Holding Report
- [Amended] Material Management Information for Investment Decisions(Korean)May 20, 2026 · Material Management Information
Filings with a published English version open in English; the rest link to the Korean original.
Hanall Biopharma (009420) stock information
KOSPI
Hanall Biopharma (009420) is listed on KOSPI. Its market capitalization is about KRW 2.7 trillion. On trailing-twelve-month earnings the P/E ratio is -119.86, and the P/B ratio is 17.23. Return on equity is -14.4%. These figures are computed in-house from official filings and are reference information only.
Hanall Biopharma — frequently asked questions
- What is the P/E ratio of Hanall Biopharma (009420)?
- On a trailing-twelve-month basis, 009420 trades at a P/E ratio of -119.86. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Hanall Biopharma?
- 009420 has a market capitalization of about KRW 2.7 trillion. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.